Europe Biotech Heavyweights Genmab And Argenx Ink Antibody Alliance
Starting With An Immunology And A Cancer Target
Executive Summary
The two flagship firms of the European biotech scene are pooling their technologies to jointly discover, develop and commercialize drugs against cancer and autoimmune diseases.
You may also be interested in...
Genmab's Growth Strategy: Embracing A ‘Super Rational, Data-Driven' Mindset
The “Genmab sauce” will be crucial as the Danish biotech loads up on late-stage assets, grows its capabilities and expands into immunology and inflammation.
Genmab On The Hunt For Late-Stage Assets
The Danish biotech has dipped its toe into co-commercialization recently and is seeking more candidates that are getting closer to the market.
Deal Watch: Japan’s SNBL To Re-Absorb US Spinout Satsuma
Shin Nippon Biomedical Laboratories would take over migraine candidate STS101, now under FDA review. Blue Water Vaccines to pick up BPH drug from Veru.